Asset profile
Vutiglabridin
Small molecule
Evidence outlook · lead readout
NCT06329141 · Parkinson Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06329141: The study randomly assigned 99 participants to two vutiglabridin doses or placebo and masked both participants and investigators. Its primary clinical outcome was change in MDS-UPDRS Part III score at Week 24, but no results or statistical comparison are currently available.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.